Dolutegravir induces FOLR1 expression during brain organoid development

Carlo Donato Caiaffa1,2, Gabriel Tukeman1, Christian Zevallos Delgado3

  • 1Center for Precision Environmental Health, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, United States.

Summary

Dolutegravir (DTG) use in early pregnancy may increase neural tube defect (NTD) risk by altering brain development. DTG impacts folate receptor expression and neurogenesis genes in organoids, suggesting a potential mechanism for NTDs.

Related Concept Videos